NCT01530295

Brief Summary

Effect of Radical Prostatectomy Combined with Neoadjuvant and Adjuvant Chemotherapy in Patients with High Risk Prostate Cancer. The purpose of this study is to evaluate whether neoajuvant and adjuvant docetaxel and prednisone are effective in the treatment of high risk localized prostate cancer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P25-P50 for not_applicable prostate-cancer

Timeline
Completed

Started Jul 2008

Typical duration for not_applicable prostate-cancer

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2008

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

June 22, 2011

Completed
8 months until next milestone

First Posted

Study publicly available on registry

February 9, 2012

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2012

Completed
Last Updated

February 9, 2012

Status Verified

February 1, 2012

Enrollment Period

4 years

First QC Date

June 22, 2011

Last Update Submit

February 7, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • biochemical recurrence rate of Radical Prostatectomy Combined with Neoadjuvant and Adjuvant Chemotherapy in Patients with High Risk Prostate Cancer

    2 Years After RRP

Study Arms (2)

contol

NO INTERVENTION

control group

Drug: DOCETAXEL

chemotherapy

OTHER

neoadjuvant chemotherapy

Drug: DOCETAXEL

Interventions

75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery

Also known as: taxotere
chemotherapycontol

Eligibility Criteria

Sexmale
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Prostate Cancer
  • PSA \> 20 OR
  • Clinical Stage \> T2C OR
  • GS \> 7

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jungmin Lee

Seoul, Seoul, 138-731, South Korea

RECRUITING

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Docetaxel

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

TaxoidsCyclodecanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsDiterpenesTerpenes

Study Officials

  • hanjong Ahn, Ph.D

    Asan Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

June 22, 2011

First Posted

February 9, 2012

Study Start

July 1, 2008

Primary Completion

July 1, 2012

Study Completion

July 1, 2012

Last Updated

February 9, 2012

Record last verified: 2012-02

Locations